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A B S T R A C T
Themain purpose of the present study was to prepare duloxetine hydrochloride (DXH) enteric-
coated pellets using different enteric polymers.Three layers (drug-loaded layer, barrier layer,
and enteric-coated layer) were applied to the inert core pellets, successively. The optimal
formulation was manufactured by employing suspension layering method in fluidized bed
processor (FBP) with varieties of enteric polymers like Aqoat® AS-LF, Eudragit® L30D55 and
HPMCP-HP55. The prepared pellets were measured for physical characterization and the in
vitro dissolution profile. Scanning electron microscopy (SEM) was conducted to observe the
morphology of pellets, and different kinetic models were applied to analyze the releasemecha-
nism of Cymbalta® and home-made pellets. The coating weight gain of enteric-coated layer
containing Eudragit® L30D55, Aqoat® AS-LF and HP-55 were determined to be 35%, 26% and
24%, respectively. The similarity factors (f2) of self-made capsules with above polymers and
commercially available capsules (Cymbalta®) were above 50 in the dissolution medium of
pH 6.8 phosphate buffer solution (PBS). SEM figures showed the smooth surfaces of self-
prepared pellets using Eudragit® L30D55 and Aqoat® AS-LF, whereas rough surface was found
in the HP-55 pellets at day 0, and an impurity was appearing in the condition of 40 °C/75%
relative humidity for 1 month. In conclusion, the pellets prepared by utilizing Eudragit® L30D55
andAqoat® AS-LF were the optimal preparations based on the dissolution profile and stability.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Duloxetine is a selective serotonin norepinephrine reuptake
inhibitor (SNRIs) currently known as a safe and effective an-
tidepressant. It is usually in the form of hydrochloride.
Duloxetine hydrochloride (DXH) enteric-coated capsule under
the name Cymbalta® has been approved for marketing by the
FDA. Cymbalta® is indicated in the United States for the treat-
ment of major depressive disorder, generalized anxiety disorder,
diabetic peripheral neuropathic pain, and fibromyalgia [1].
Pellets, multi-part dosage forms, have both pharmaceuti-
cal and therapeutic advantages.Their pharmaceutical benefits
including the flexibility in development and design enable the
administration of incompatible bioactive compounds owing to
the low surface-area-to-volume ratio compared with gran-
ules and powders.Therapeutic advantages involve enhancement
of bioavailability, decrease of irritation and alteration of mecha-
nism of drug release in the gastrointestinal tract (GIT) when
administered orally. Consequently, pellets acting as a sub-
strate of drug are able to be coated with large amounts of drugs
and excipients.
Owing to the lability of DXH at pH value less than 2.5, enteric
polymers should be applied to prevent acid degradation of
DXH in the stomach and provide for rapid drug-release in the
small intestine. In this study, several enteric polymers have
been employed, such as Eudragit® L30D55, hydroxyl propyl
methyl cellulose acetate succinate (HPMCAS) and hydroxyl
propyl methyl cellulose phthalate (HPMCP). Eudragit® L30D55
is an anionic copolymer of methacrylic acid and ethyl acry-
late, and the ratio of carboxyl to ester group is 1:1.The backbone
structures of HPMCAS and HPMCP are all water-soluble poly-
mers, HPMC.HPMCP contains a carboxybenzoyl (phthalyl) group,
which can define the solubility of HPMCP, while HPMCAS in-
cludes acetyl and succinyl groups, and its solubility is
determined by their ratio. The polymers have very low solu-
bility in water due to their hydrophobic nature, when their
carboxyl groups are in undissociated form.The structure state
of polymer shifts to the formation of the ionized form with
increasing water solubility as the pH rises. Thus, the pH can
be controlled by adjusting the phthalyl content to make HPMCP
soluble. HP-55 and HP-50 are dissolved at a pH around 5.5
and 5.0, respectively. In the same way, HPMCAS-LF (Aqoat®
AS-LF) with 8% acetyl and 15% succinyl can be soluble at a
pH around 5.5. HP-55 and HPMCAS-LF are selected, because
Cymbalta® has been proven to release the drug from pH 5.5
PBS. If the described polymers are employed, we should pay
attention to their stability with duloxetine. It is the residual
free acids group present in HPMCAS or HPMCP that has been
found to react with DXH, and the reactions form succinamide
or phthalamide impurities accelerated by humidity and heat
[2]. Thus, the barrier layer is an indispensable part of pellets
to separate the drug from polymers and improve the stability
of preparation.
The aim of the present study is to (a) prepare duloxetine
hydrochloride enteric-coated pellets using several enteric poly-
mers; (b) evaluate the effect of the type of enteric polymer,
coating weight, pH of enteric polymers and curing conditions
on gastric stability and in vitro dissolution; and (c) investigate
the drug stability by accelerated test.
2. Materials and methods
2.1. Materials
Duloxetine hydrochloride was purchased from ShanghaiWonder
Pharmaceutical Co. Ltd. (Shanghai, China). Sucrose-starch non-
pareils were from Hangzhou Gaocheng Biotech & Health Co.
Ltd. (Hangzhou, China). Hydroxy-propyl methylcellulose E5
(HPMC-E5) was kindly provided by Shanhe Pharmaceutical Co.
Ltd. (Anhui, China), and methacrylic acid copolymer (Eudragit®
L30D55) was from Evonik (Germany). The polymers of hy-
droxyl propyl methyl cellulose acetate succinate-LF (Aqoat® AS-
LF) and hydroxyl propyl methyl cellulose phthalate (HPMCP)
were obtained from Shin-Etsu Chemical Co. Ltd. (Japan) and
Samsung Fine Chemicals Co. Ltd. (Korea). No.3 hard gelatin
capsule shells were from Suzhou Capsule Co. Ltd. (Suzhou,
China). Commercially available duloxetine delayed-release cap-
sules (Cymbalta®, 30 mg/capsule, Eli Lilly and Company, USA)
were chosen for comparison. All organic solvents used in HPLC
were of high-performance liquid chromatography (HPLC) grade.
All other ingredients were of analytical grade.
2.2. Methods
2.2.1. Preparation of pellets
Duloxetine hydrochloride delayed-release pellets were com-
posed of four parts, namely nonpareils (sugar spheres), drug
layer, barrier layer and enteric-coated layer successively. All the
layers were prepared in a fluidized bed processor (Table 1) by
the suspension layer method. Drug layer could also be manu-
factured by a centrifugal granulator (Table 2).
HPMC-E5 was applied both as binder and as barrier polymer
because of its low molecular weight (MW) and its application
Table 1 – Various process parameters of three layers in fluidized bed processor.
S. No. Parameters Drug layer Barrier layer Enteric-coated layer
1 Inlet temperature (°C) 55–60 50–55 45–50/55–60
2 Outlet temperature (°C) 50–55 45–50 40–45/50–55
3 Product temperature (°C) 40–45 38–40 35–40/40–45
4 Atomization (Bar) 1.0–1.5 1.5–2.0 1.5–2.0
5 Air flow (m3/h)a 50–55 45–50 50–55
6 Spray rate (g/min)a 5–7 4–6 4–7
a Adjusted according to the experimental conditions in the process of drug-loading or coating.
ARTICLE IN PRESS
Please cite this article in press as: Chen Kuang, et al., Preparation and evaluation of duloxetine hydrochloride enteric-coated pellets with different enteric polymers, Asian
Journal of Pharmaceutical Sciences (2016), doi: 10.1016/j.ajps.2016.08.007
2 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s ■■ ( 2 0 1 6 ) ■■ –■■
of serving as good pelletization aid [3].When sucrose was added
to the barrier layer, the resistance of pellets to acid condi-
tions was remarkably increased [4]. It was suggested that
sodium chloride with HPMC provided functional barrier, which
avoided the migration of acidic ingredients between layers and
thus capacitated stabilization of duloxetine [5]. Eudragit® L30D55,
Aqoat® AS-LF and HPMCP-HP55 were the three chosen enteric
polymers.
The drug-loaded and barrier-layer-loaded pellets should be
dried for 2 h at 40 °C, and then weighted to calculate the weight
gain when their temperature reached room temperature.There
was difference in the curing condition of three enteric poly-
mers. Eudragit® L30D55 required only 2 hours under 40 °C to
be cured, while Aqoat® AS-LF and HPMCP-HP55 were fully cured
under 40/60 °C for more time. After the curing, the pellets were
collected and weighted to calculate the weight gain. In the fol-
lowing study, we investigated the effect of curing condition on
the dissolution.
2.2.1.1. Drug layer. DXH (101 g) was pulverized by dry grind-
ing and passed through 200-mesh sieve. Two hundred grams
of blank pellets (600–710 μm) was weighted to FBP or centrifu-
gal granulator. HPMC-E5 (2%, wt/wt) was added to 500 ml
distilled water that had been heated to 60–70 °C in advance,
stirring constantly until fully dissolved.The suspension of drug
layer was built up by incorporating duloxetine hydrochloride
intermittently into the HPMC-E5 solution with constant stir-
ring at room temperature.The achieved suspension was coated
onto the sugar spheres. In the process, the drug suspension
must be stirred constantly. The pellets (24–30 mesh) were ul-
timately sieved to prepare the barrier layer.
2.2.1.2. Barrier layer. Barrier layer, also called separating layer,
physically kept the components in the drug layer and enteric
layer from coming into direct contact with each other. Sucrose
(32%, wt/wt, based on the total dry weight of barrier layer) was
dissolved in the 2% wt/wt solution of the HPMC-E5 in water
(400 ml), namely solution A. Micronized talc (50%, wt/wt, based
on the total dry weight of barrier layer) was dispersed in dis-
tilled water (400 ml), and then an opacifying agent like titanium
dioxide (TiO2) (5%,wt/wt, based on the total dry weight of barrier
layer) was added to protect the duloxetine from light, namely
solution B. Solutions A and B were blended with continuous
stirring to be homogeneous. In the process, the barrier-
coating dispersionmust be stirred continuously.The suspension
of separating layer was prepared to gain 15% of drug-loaded
pellets. Eventually, the pellets (24 to 30 sieve mesh) were sieved
to prepare the enteric-coated layer.
2.2.1.3. Enteric-coated layer.
a. Eudragit® L30D55 was added to part of purified water (30%,
wt/wt, based on the aqueous dispersion of polymer) under
stirring, and then mixed for 5 minutes. Fine talc (7%, wt/
wt, based on the aqueous dispersion of polymer) was
dispersed with constant stirring in distilled water, which
was dropped with triethyl citrate (TEC) (3%, wt/wt, based
on the aqueous dispersion of polymer), and then added to
the above suspension. The solution was blended for 15
minutes until a homogenous dispersion was formed. The
suspension can be neutralized to the wanted pH using
0.1 mol/l sodium hydroxide solution. The prepared pellets
were cured for 2 h at 40 °C.
b. HPMCAS-LF (6%, wt/wt, based on the solution) was well-
dispersed in the purified water cooled to 15 °C or below.To
this suspension,TEC (20%,wt/wt, based on the polymer) and
talc (30%, wt/wt, based on the polymer) were added and
blended thoroughly until homogeneity was obtained. The
enteric suspension should be maintained below 20 °C.A part
of or all the enteric polymer was neutralized with ammo-
nium hydroxide, which was able to prevent the spray gun
nozzle from blocking at room temperature. The prepared
pellets were cured for 3 h at 60 °C.
c. Ethanol and purified water were prepared at the ratio of 8:2
in a clean beaker. HPMCP-HP55 (8%, wt/wt, based on the so-
lution) was slowly added to the obtained solvent and
dissolved for 1 hour under constant stirring. TEC (10%, wt/
wt, based on the polymer) and talc (30%, wt/wt, based on
the polymer) were added to the above solution and a uniform
suspension was obtained with continuous stirring.The pre-
pared pellets were cured for 2/4 h at 40 °C.
Eventually, the pellets (20 to 30 sieve mesh) were screened
for encapsulation.
2.2.2. Characterization of optimized pellets
Qualified pellets with different kinds of enteric polymers were
evaluated by yield of pellets, angle of repose, friability and par-
ticle size distribution. The yield of pellets was calculated by
the following formula (1)
yield of pellets
Practicle yield of pellets
Theoretical yield o
%( ) =
f pellets
× 100% (1)
Fixed funnel method was chosen to determine the angle
of repose. The powder of DXH was poured through a funnel
to form a cone. The tip of the funnel should be held closely
to the growing cone and slowly raised as the pile grows. No
pouring the powder when the pile reached a predetermined
height or the base reacted to a predetermined width. Rather
than attempt to measure the angle of the resulting cone di-
rectly, we divided the height by half the width of the base.The
inverse tangent of this ratio was the angle of repose.
Table 2 – Various process parameters of drug layer in
centrifugal granulator.
S. No. Processing parameter Value
1 Rotational speed of plate 200 rpm
2 Blower rate 10 × 14 l/min
3 Air flow rate 10 l/min
4 Spray air pressure 0.5 MPa
5 Spray rate of solutiona 4–7 g/min
6 Rotating rate of powder feederb 0–15 rpm
7 Inlet temperature (°C) 35
8 Outlet temperature (°C) 25
a The spray rate was 4 g/min for the first 10 min, and gradually in-
creased to 7 g/min until the end.
b The rotating rate of feeder was 0 rpm for the first 10min, and gradu-
ally increased to 15 rpm until the end.
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Friability was tested by a friabilator. Ten grams of home-
pellets and 25 glass balls were mixed together to be centrifuged
for 10 min at 30 rpm.The pellets were collected and weighted.
As a result, the percentage of weight loss of the pellets was
calculated [6]. Sieve analysis was applied for particle size and
distribution. One hundred grams of pellets was collected and
divided into three parts (20–24 mesh, 24–30 mesh and 30–40
mesh) according to the particle size.
A certain amount of weight of pellets was weighed out
(equivalent to 30 mg duloxetine), and then were packed in No.3
capsule shell for future use.
2.2.3. Determination of drug content
The drug content was determined by the method of HPLC.
Agilent ZORBAX SB-C8 column (3.5 μm, 75 × 4.6 mm) was op-
timized in a column oven with the temperature maintained
45 °C.The injection volume was 10 μl, the flow rate was 1.5 ml/
min, and the UV detector wavelength was set at 230 nm.
For buffer A, 3.4 g/l of monobasic potassium phosphate in
water was prepared. Fifteen milliliters of triethylamine was
added to 1 l of this solution, and adjusted with phosphoric acid
to a pH of 5.5 ± 0.2.
For buffer B, 216 mg/l of monobasic ammonium phos-
phate and 4.5 g/l of dibasic potassium phosphate were prepared
in water, and adjusted with ammonia or phosphoric acid to a
pH of 7.9–8.3.
Mobile phase was formed from methanol, tetrahydrofu-
ran and buffer A (323:90:587).
The contents of NLT 10 capsules were ground with a mortar
and pestle into fine powders.Then powders (equivalent to ap-
proximately 90 mg duloxetine) were precisely weighed and
transferred into a 100 ml volumetric flask. Half of the mixed
diluent (buffer B and acetonitrile with the ratio of 60:40 (v/v))
was added, and the contents in the flask were shaken for 10
minutes after sonication for 3 minutes.The solution was then
diluted to the mark with uniform diluent to get a stock solu-
tion, which was filtered through a 0.45 μmmembrane filter. Five
millimeters of the filtrate was diluted to 50 ml with the mixed
diluent, and the diluted solution was filtered to get sample so-
lution as before [7].
2.2.4. Drug release measurements and comparisons
Enteric-coated capsules prepared from Eudragit® L30D55,Aqoat®
AS-LF and HPMCP-HP55 were tested in 1000 ml of 0.1 mol/l HCL
(simulated gastric fluid) followed by the phosphate buffer of
pH 6.8 using apparatus 1 (basket apparatus) in USP. One liter
of 0.1 mol/l HCL was transferred into each container of the ZRS-
8G Test Dissolution Tester (Tianjin University Radio Factory,
Tianjin, China), in which medium can be maintained at
37 ± 0.2 °C. DXH capsule equivalent to 30 mg duloxetine was
placed in each of the baskets, and the baskets were fixed to
shafts and operated dissolution apparatus at 100 rpm for 2
hours.After 2 hours in acid, 0.1 mol/l HCL was carefully drained
and the fresh solution of 1000 ml of pH 6.8 phosphate buffer
(simulated intestinal fluid),maintained at 37 ± 0.2 °C in advance,
was taken into the container. At each specified interval of time,
5.0 ml of the sample was withdrawn from each container and
replaced with equal volume of fresh pH 6.8 medium main-
tained at 37 ± 0.2 °C for 1 h. The collected sample was filtered
through 0.45 μm membrane filter and analyzed with HPLC as
the assay of drug content [7].
In this study, we evaluated the similarity between home-
made capsules and marketed capsule (Cymbalta®) in the pH
6.8 phosphate buffer. As a parameter of similarity evaluation,
the similarity factor (f2) plays a significant role in comparing
the dissolution profiles. f2 (shown in the following formula (2))
is a logarithmic transformation of the sum-squared error of
differences between the reference and the tested prepara-
tions over all time points [8].
f
n
R Tt t
t
n
2
2
1
1 2
50 1
1
100= × + −( )⎡⎣⎢
⎤
⎦⎥ ×
⎧⎨⎪⎩⎪
⎫⎬⎪⎭⎪=∑log (2)
Log stands for logarithm based on 10. It is recommended
that two dissolution profiles can be determined to be similar
when f2 value exceeds 50.
2.2.5. Scanning electron microscopy (SEM)
To evaluate the surface morphology of enteric-coated polymer
membrane with different polymers, scanning electron micros-
copy (SEM) (SU8010, HIGUCHI, Japan) images were achieved from
Cymbalta® and home-made pellets. The pictures were taken
at the magnification of 90× or 80×.
2.2.6. Kinetic models of reference and optimized formulations
Kinetic studies were conducted for reference and optimizing
enteric-coated formulations with different polymers. It was in-
ferred that there were three probable ways for drug release from
the polymeric membrane to medium: (1) the drug is dis-
persed into the membrane and permeated through the
consistent polymeric network, and then redistributed in the
polymeric framework and diffused to the medium; (2) the drug
is dispersed to medium via tiny holes or cracks existing in the
membrane; and (3) the coalition of the above two [9–12].
Different mathematical models were applied to study the
in vitro dissolution behaviors of the pellets, including zero-
order model [13], first-order model [14], Higuchi model [15],
Ritger–Peppas model [16], Hixson–Crowell model, Baker–
Lonsdale model [17] andWeibull model [18]. Regression analysis
was conducted, and then the best fits were calculated based
on correlation coefficient as r [12].
Of the models above, Ritger–Peppas model [16] was applied
for further analyses of drug release mechanism. Equation of
Ritger–Peppas model was shown in the following formula (3).
Qt denoted the accumulated release at time (t), kR expressed
the constant rate of drug release, while n was an important
parameter indicating the release mechanism. If “n” ≤ 0.45, the
mechanism was Fickian diffusional. If 0.45 < “n” < 0.89, the
release mechanism was non-Fickian dispersion including
Fickian-diffusional and relaxation. If the “n” ≥ 0.89, the relax-
ation played a sole role in drug release.
ln lnQ n t kt R= + (3)
2.2.7. Stability study
The optimized enteric-coated pellets and Cymbalta® were
placed into the condition of 40 °C/75% RH for 1 month. Samples
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were analyzed for the dissolution profiles, contents and related
substances.
3. Results and discussion
3.1. DXH drug-layer pellets prepared by different
apparatus
Drug-layer pellets were prepared with two kinds of instru-
ments, centrifugal granulator and fluidized bed. The above
equipments were both used to search the optional formula-
tion and preparation technique. It was the same in temperature
and relative humidity of environment.The pellets prepared by
fluidized bed, had lower friability (0.07%) and higher yield (93.2%)
than that prepared by centrifugal granulator (0.18%, 75.3%).
Pellets manufactured by centrifugal granulator were coated with
barrier suspension by fluidized bed, in the process of which,
the powder could desquamate from the drug-layer pellets. Con-
sequently, it was the loss of DXH that led to the rough surface
and low yield. In addition, there was a drawback in the prepa-
ration process that dust emissions happened due to low density
of drug.
3.2. Physical characterization of enteric-coated pellets
The optimal enteric-coated pellets were achieved with
85.3 ± 0.2% of yield, 25.2 ± 0.9° of angle of repose, and 0.07 ± 0.02%
of friability.The percentage of pellets obtained from 20–24mesh,
24–30 mesh, and 30–40 mesh were 88%, 10% and 2%,
respectively.
3.3. Effect of particle size of duloxetine hydrochloride on
drug release
According to BCS, duloxetine hydrochloride is classified as class-
II drug and has limited aqueous solubility. It was proven by the
experiment that duloxetine hydrochloride was sparingly soluble
in water [19]; thus particle size was decreased to increase the
solubility and dissolution rate of duloxetine hydrochloride.
Duloxetine hydrochloride was smashed by pulverizer, then, was
passed through 80-mesh or 200-mesh sieve. Different par-
ticle sizes of duloxetine hydrochloride were sprayed to sugar
spheres homogeneously to compare the differences on the drug
release. Fig. 1A showed the release profiles of duloxetine from
drug-loaded pellets at pH 6.8. It can be concluded that pellets
with 200-mesh DXH have higher solubility and dissolution rate
than 80-mesh.
3.4. Inspection of the concentration of HPMC-E5 in DXH
solution
In the process of drug-loading, HPMC-E5 played a role of
adhesion, so the drug could adhere to the sugar-spheres.
Different concentrations of HPMC-E5 solution (1.0%, 2.0%
and 3.0%, wt/wt) were prepared to estimate their impact on
the preparation procedure and drug release. 1.0% HPMC
solution was sprayed on the blank pellets, which could result
in high friability because of the low viscosity. The viscosity of
3.0% HPMC-E5 solution was high enough to make the pellets
agglomerate on the side of fluidized bed so that the drug-
spraying process could not run continuously. However, 2.0%
HPMC-E5 solution could prevent the above problems from
occurring and enabled the industrial manufacture to reality.
Fig. 1B expressed the dissolution profiles of duloxetine drug-
loaded pellets coated with different concentrations of adhesion.
It was concluded that 2.0% HPMC-E5 solution was the opti-
mized adhesion because of its higher dissolution and smoother
preparation process.
3.5. The impact of environmental aspect (temperature
and relative humidity) on drug-laying and coating
Drug-laying and barrier-laying temperature could be con-
trolled in the range of 40–50 °C.Too low temperature could lead
to long working hours.Too high temperature could reduce the
Fig. 1 – Release profiles (mean ± SD, n ≥ 3) of duloxetine
from drug-loaded pellets with (A) different particle sizes of
drug; (B) different concentrations of HPMC-E5 solution, at
pH 6.8.
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stability of duloxetine. Besides, the temperature should be regu-
lated along with relative humidity.
Temperature not only had impact on the enteric-coating
process, but also determined the physico-chemical property
of membrane. Too high or low temperature could conse-
quently make an effect on the intactness of the enteric-
membrane and influence the drug-release behavior. Different
temperatures were demanded over the membrane formation
of the three polymers. In the process of coating with Eudragit®
L30D55, it was required that inlet temperature was regulated
at 40–45 °C to make the temperature of pellets controlled at
28–30 °C. Inlet temperature could be adjusted to 55–60 °C
during the coating with Aqoat® AS-LF and HPMCP-HP55.
Moreover, to prevent nozzle clogging, it was recommended
to chill the coating suspension with ice bath when using
Aqoat® AS-LF, if necessary, to maintain the temperature
under 25 °C [4].
Furthermore, relative humidity was another principal
element affecting coating procedure. Electrostatic phenom-
enon would generate between pellets and inner wall of fluidized
bed when the relative humidity was extremely low, resulting
in inhomogeneous coating. Especially, the phenomenon was
remarkable when using organic solvent as enteric-coating
solvent. Nevertheless, pellets would agglomerate in case of the
high relative humidity that led to the adverse fluidization con-
dition of pellets.According to the experience, the coating process
could be accomplished successfully in the environment at a
controlled relative humidity of 30%–50% [12].
3.6. Release of duloxetine from pellets coated with
Eudragit® L30D55
3.6.1. Effect of the coating weight on dissolution profile in pH
6.8 PBS
First of all, the enteric-coated solution was prepared to make
18% coating weight gain.Then, some enteric-coated pellets were
taken out from discharge hole of FBP respectively when the
coating weight gain reached 10%, 12% and 15%. As seen in
Fig. 2A, percentage of duloxetine released in the acid stage
medium after 2 h decreased with the increase of coating
amount. The release of duloxetine was restrained completely
in the acid medium if the enteric-coated weight of pellets was
added to 18%. It was because the diffusion path length in-
creased.The accumulative drug-release of pellets at pH 6.8 was
instead increased when making the coating amount gained.
It was the reaction of 0.1 mol/l HCL with polymer or duloxetine
probably that interfered in the dissolution of drug in the fol-
lowing pH 6.8 PBS.
Subsequently, the coating weight was increased to 23%, 29%,
35% and 45%. The release amount of above pellets was 0% in
the 0.1 mol/l HCL solution. As we can see in Fig. 2B, the accu-
mulative release of home-made pellets at 60 min corresponded
to Cymbalta® if the enteric-coated weight of home-made pellets
increased to 29%. According to f2 (Table 3), duloxetine pellets
coated with 35% is the optimal formation for Eudragit® L30D55.
However, in the first 20 minutes, the pellets coated with 35%
Eudragit® L30D55 were released more slowly than the mar-
keted. There was a probability that the structure of polymers
was a key for the dissolution rate. As a result, we utilized other
enteric-coated polymers to make the experiment.
3.7. Release of duloxetine from pellets coated with Aqoat®
AS-LF
3.7.1. Effect of the coating weight on dissolution profile in pH
6.8 PBS
As seen in Fig. 3A, percentage of duloxetine released in the
acidic medium after 2 h decreased with the increase of coating
amount. The release of drug in the acid medium was reduced
to less than 10%, when enteric-coated weight of pellets added
to 20%. According to the resistance to acid and f2 (Table 3),
duloxetine pellets coated with 24% was the best formulation
for Aqoat® AS-LF.When using Aqoat® AS-LF, the dissolution rate
was more rapid compared to Eudragit® L30D55.
3.7.2. Effect of pH of enteric polymer on dissolution profile in
pH 6.8 PBS
We preferred to apply the enteric polymer as an aqueous so-
lution.Aqoat® AS-LF was insoluble in water, but it could be easily
Fig. 2 – Release profiles (mean ± SD, n ≥ 3) of duloxetine
pellets coated with Eudragit® L30D55 (A) affected by weight
gain (10–18%); (B) affected by weight gain (23–45%), and
Cymbalta® after 2 h 0.1 mol/l HCL and subsequently at pH
6.8.
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dissolved by neutralizing the polymer preferably with ammo-
nium [4].As seen in Fig. 3B,with weight gain of enteric polymers
unchanged, enteric-coated pellets with NH3 had lower disso-
lution rate. If enteric weight increased to 30%, the dissolution
rate was higher than 25% (Fig. 3C). Moreover, f2 of pellets (30%
weight-gain) was enhanced to over 50 (Table 3).
3.8. Release of duloxetine from pellets coated with
HPMCP-HP55
3.8.1. Effect of curing condition on dissolution profile in pH
6.8 PBS
It was proposed that the curing temperature or time was in-
creased to improve film formation and hence coating
performance [20]. Pellets with HPMCP were found to form
phthalamide impurity when accelerated by heat and humid-
ity [2]. Therefore, only the curing time was modified from 2 to
4 hours, maintaining the curing temperature at 40 °C. Fig. 4A
expressed that increasing curing time to 4 h slightly de-
creased release after 2 h in 0.1 mol/l HCL (1.08% → 0%), while
it significantly increased release at pH 6.8.
3.8.2. Effect of the coating weight on dissolution profile in pH
6.8 PBS
As seen in Fig. 4B, percentage of duloxetine released in 0.1 mol/l
HCL after 2 h had remained at 0% with the increase of coating
weight gain. According to f2 (Table 3), with HPMCP-HP55,
duloxetine enteric-pellets coated with 26% was the best for-
mulation.When HP-55 was used, the dissolution rate was the
same with Cymbalta®.
3.9. Effect of the type of enteric polymer on dissolution
profile in pH 6.8 PBS
The dissolution profile of preparations with the above three
polymers was summarized in Fig. 5. We selected the three
enteric-coated pellets with the same weight gain, and then the
figure could suggest that the different enteric polymers have
varied resistance to acids and release rate in intestinal juice.
Table 3 – The f2 of dissolution profiles of home-made
and marketed pellets in pH 6.8 PBS.
Enteric polymers Enteric-coated
weight gain (%)
f2
Eudragit® L30D55 23 48
29 54
35 61a
45 51
Aqoat® AS-LF without NH3 17 36
20 68a
24 60
Aqoat® AS-LF with NH3 25 49
30 53
35 47
HPMCP-HP55 17 59
26 63
34 57
a The maximums of similarity factor of preparations used by dif-
ferent polymers were emphasized.
Fig. 3 – Release profiles (mean ± SD, n ≥ 3) of duloxetine
pellets coated with Aqoat® AS-LF (A) affected by weight
gain without NH3; (B) affected by the enteric suspension
with or without NH3; (C) affected by weight gain with NH3,
and Cymbalta® after 2 h 0.1 mol/l HCL and subsequently at
pH 6.8.
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When aqueous coatings are employed, it is necessary to
apply more coating polymers to achieve the desired effect such
as resistance to gastric fluid or delay in release, than with com-
parable organic coatings [21]. In our research,Aqoat® AS-LF was
well-dispersed in the distilled water, while HPMCP-HP55 was
dissolved in the 80% ethanol solution. Consequently, the pellets
could better achieve gastro-resistance with 17% HPMCP-HP55
than with 17% Aqoat® AS-LF.
It becomes clear that a factor governing the rate of solu-
tion and solubility of HPMCAS is the electrostatic free energy
of dissociation of carboxyl groups [22]. That could be true for
HPMCP-HP55 and Eudragit® L30D55. When the polymers are
in the higher pH condition, they could combine with hy-
droxyl ions to form salt. Due to the repulsive interaction of
ionized carboxyl, the empty space between themolecules would
become larger leading to the loose structure, and thus drug was
released from the film.The backbone structure of HPMCAS and
HPMCP are the same, HPMC, which is different from Eudragit®
L30D55. Eudragit® L30D55 is an anionic copolymer of meth-
acrylic acid and ethyl acrylate.The monomers of HPMCAS and
HPMCP have two carboxyl groups, while that of Eudragit®
L30D55 has only one. It was probably less carboxyl group that
resulted in the lower dissolution rate for Eudragit® L30D55.
Further research is needed to prove this.
3.10. SEM experiments
Enteric-coated pellets were examined under scanning elec-
tron microscopy at ×90 or ×80 magnifications. The electron
photomicrographs were shown in Fig. 6. The surfaces of the
coated pellets were all round. Pellets coated by Eudragit® L30D55
and Aqoat® AS-LF were smooth as Cymbalta®, while the one
coated with HPMCP-HP55 was rough extraordinarily.
The aqueous dispersion of HP-55 could be micronized and
film formation was improved by minimizing its particle size
[23]. In addition to the loss of plasticizer (TEC) and lessened
protection against moisture, it was possible for dispersion coat-
ings to show a more porous membrane or cracks along with
remaining particle borders, particularly [24]. The drug release
characteristics of the preparation could be altered and stick-
ing would occur with a decline in the functional property of
the films. Sticking could be refrained by means of applying a
plus overcoat of water-soluble cellulose material such as HPC
or HPMC [25]. Consequently, we will attempt to add a finish-
ing layer over the enteric layer to improve the elegance of the
pellets and its storage.The same impact can be exerted on the
HP-55 if decreasing the polymer size.
3.11. The mechanism of drug release
The different kinetic models were applied to marketed refer-
ence and the different enteric-coated formulations, and the
results were shown in Table 4. It was observed that First-
order model, Hixson–Crowell model and Weibull model were
all fitted for Cymbalta®, andWeibull model was the best. Home-
made pellets applied with polymers of Eudragit® L30D55,Aqoat®
Fig. 4 – Release profiles (mean ± SD, n ≥ 3) of duloxetine
pellets coated (A) with 17% HPMCP-HP55 affected by curing
time under 40 °C; (B) affected by weight gain with HP-55,
and Cymbalta® after 2 h 0.1 mol/l HCL and subsequently at
pH 6.8.
Fig. 5 – Release profiles (mean ± SD, n ≥ 3) of duloxetine
pellets coated with different enteric polymers after 2 h 0.1
mol/l HCL and subsequently at pH 6.8.
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AS-LF and HPMCP HP-55 were consistent with the marketed.
The “n” of Ritger–Peppas model was 0.7386 of Cymbalta®, while
the “n” were 0.8150, 0.6225 and 0.7642 of Eudragit® L30D55,
Aqoat® AS-LF and HPMCP-HP55, respectively. As a conse-
quence, we can draw the conclusion that both free diffusion
and relaxation play a key role in the drug release of Cymbalta®
and home-made products.
3.12. Results of stability study
The optimized enteric-coated pellets were selected on the basis
of abovementioned results. Fig. 6 showed that the dissolu-
tion profiles of marketed and home-made capsules had no
noticeable difference after storage under the condition of 40 °C/
75% relative humidity for 1 month.
As shown in Table 5, the home-made pellets manufactured
using Eudragit® L30D55 andAqoat®AS-LFwere relatively stable.
The pellets could be unable under the accelerated test for longer
than onemonth, and hence home-made pellets and Cymbalta®
need more evaluation. However, there was an unknown im-
purity in the HP-55 pellets after storage at 40 °C/75% relative
humidity for 1 month (Fig. 8). It was demonstrated that the re-
sidual free acids existing in the enteric polymers HPMCP and
HPMCAS in pellets form phthalamide and succinamide im-
purities respectively, under the accelerated condition of heat
and humidity. It was postulated that phthalic and succinic sub-
stituents could be cleaved from the polymers, leading to the
formation of either anhydrides or free acids. It was proposed
that the reaction was motivated by the migration of either (1)
the anhydride or free acid or (2) the drug substance through
the formulations. Formation of the impurities was minimized
by way of increasing the thickness of the barrier-layer [2]. The
structure of the unknown impurity can be analyzed by nuclear
magnetic resonance (NMR).
The γ-scintigraphy studies, in vivo, had revealed that there
was a substantial time delayed (up to 2 h) for such pellets to
disintegrate in the small intestine after the emptying of the
stomach, with different enteric-polymers owning various
Table 4 – Kinetic models of drug release and correlation coefficient.
Kinetic model Equation r
Cymbalta® Home-made
Eudragit® L30D55 Aqoat® AS-LF HPMCP (HP-55)
Zero-order model Q k tt = 0 0.8873 0.9273 0.8429 0.9337
First-order model ln lnQ Q k t Qt0 1 0−( ) = − + 0.9750 0.9561 0.9741 0.9753
Higuchi diffusion model Q k tt H=
1
2 0.9234 0.8810 0.9293 0.9118
Ritger–Peppas model ln lnQ n t kt R= + 0.9502 0.9414 0.9442 0.9599
Baker–Lonsdale model
3
2
1 1
2
3− −( )⎡⎣⎢
⎤
⎦⎥ − =Q Q kt t BL 0.8746 0.8347 0.8843 0.8597
Hixson–Crowell model 1 1
1
3−( ) = −Q kt HC 0.9762 0.9550 0.9761 0.9718
Weibull model Q et t= − −1 α
β
0.9972 0.9909 0.9923 0.9957
Fig. 6 – Scanning electron microscopy figures of optimal pellets (A: Cymbalta®; B: Aqoat® AS-LF; C: HPMCP-HP55; D:
Eudragit® L30D55).
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disintegration times [26,27]. Therefore, dissolution research is
recommended to be evaluated in the dissolution medium of
lower pH like pH 5.5 PBS and pH 6.0 PBS, instead of pH 6.8 PBS
[28].
4. Conclusions
Duloxetine hydrochloride enteric-coated capsules were suc-
cessfully prepared in a laboratory-scale, with three polymers
including Eudragit® L30D55, Aqoat® AS-LF and HPMCP-HP55.
The in vitro release behaviors of above three preparations were
similar to that of Cymbalta®. However, the pellets prepared with
HPMCP-HP55 had poorer stability than that with two other poly-
mers. We can draw a conclusion that drug release can be
affected if the coating weight, pH of enteric polymers and curing
conditions are changed. In conclusion, the pellets prepared by
utilizing Eudragit® L30D55 and Aqoat® AS-LF were the optimal
preparations based on the drug release and stability. The self-
made pellets with HP-55 will be manufactured through thicker
Table 5 – Stability of marketed and home-made pellets exposed to the accelerated condition.
Product Time Content property Related substance(%) Content(%) Dissolution profile
Cymbalta® 0-day White-pellets – 99.90 Fig. 7A
1-month White-pellets – 99.32
Homemade Eudragit® L30D55 0-day White-pellets – 98.98 Fig. 7B
1-month White-pellets – 98.52
Aqoat® AS-LF 0-day White-pellets – 99.95 Fig. 7C
1-month White-pellets – 100.16
HPMCP (HP-55) 0-day White-pellets – 100.00 Fig. 7D
1-month White-pellets 0.2 98.56
Fig. 7 – Release profiles (mean ± SD, n ≥ 3) of (A) Cymbalta® and home-made pellets by (B) Eudragit® L30D55; (C) Aqoat® AS-
LF; (D) HPMCP-HP55, in day 0 and after accelerated test of 1 month after 2 h 0.1 mol/l HCL and subsequently at pH 6.8.
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barrier-layer or by adding a finishing layer to enhance the
stability.
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Fig. 8 – HPLC chromatogram of duloxetine hydrochloride
pellets prepared by HPMCP-HP55 stressed at 40 °C/75%
relative humidity for 1 month.
ARTICLE IN PRESS
Please cite this article in press as: Chen Kuang, et al., Preparation and evaluation of duloxetine hydrochloride enteric-coated pellets with different enteric polymers, Asian
Journal of Pharmaceutical Sciences (2016), doi: 10.1016/j.ajps.2016.08.007
11a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s ■■ ( 2 0 1 6 ) ■■ –■■
